Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Skin care interventions in infants for preventing eczema and food allergy

      systematic-review

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Eczema and food allergy are common health conditions that usually begin in early childhood and often occur in the same people. They can be associated with an impaired skin barrier in early infancy. It is unclear whether trying to prevent or reverse an impaired skin barrier soon after birth is effective for preventing eczema or food allergy.

          Objectives

          Primary objective

          To assess the effects of skin care interventions such as emollients for primary prevention of eczema and food allergy in infants.

          Secondary objective

          To identify features of study populations such as age, hereditary risk, and adherence to interventions that are associated with the greatest treatment benefit or harm for both eczema and food allergy.

          Search methods

          We performed an updated search of the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, and Embase in September 2021. We searched two trials registers in July 2021. We checked the reference lists of included studies and relevant systematic reviews, and scanned conference proceedings to identify further references to relevant randomised controlled trials (RCTs). 

          Selection criteria

          We included RCTs of skin care interventions that could potentially enhance skin barrier function, reduce dryness, or reduce subclinical inflammation in healthy term (> 37 weeks) infants (≤ 12 months) without pre‐existing eczema, food allergy, or other skin condition. Eligible comparisons were standard care in the locality or no treatment. Types of skin care interventions could include moisturisers/emollients; bathing products; advice regarding reducing soap exposure and bathing frequency; and use of water softeners. No minimum follow‐up was required.

          Data collection and analysis

          This is a prospective individual participant data (IPD) meta‐analysis. We used standard Cochrane methodological procedures, and primary analyses used the IPD dataset. Primary outcomes were cumulative incidence of eczema and cumulative incidence of immunoglobulin (Ig)E‐mediated food allergy by one to three years, both measured at the closest available time point to two years. Secondary outcomes included adverse events during the intervention period; eczema severity (clinician‐assessed); parent report of eczema severity; time to onset of eczema; parent report of immediate food allergy; and allergic sensitisation to food or inhalant allergen.

          Main results

          We identified 33 RCTs comprising 25,827 participants. Of these, 17 studies randomising 5823 participants reported information on one or more outcomes specified in this review.  We included 11 studies, randomising 5217 participants, in one or more meta‐analyses (range 2 to 9 studies per individual meta‐analysis), with 10 of these studies providing IPD; the remaining 6 studies were included in the narrative results only.  

          Most studies were conducted at children's hospitals. Twenty‐five studies, including all those contributing data to meta‐analyses, randomised newborns up to age three weeks to receive a skin care intervention or standard infant skin care. Eight of the 11 studies contributing to meta‐analyses recruited infants at high risk of developing eczema or food allergy, although the definition of high risk varied between studies. Durations of intervention and follow‐up ranged from 24 hours to three years. All interventions were compared against no skin care intervention or local standard care. Of the 17 studies that reported information on our prespecified outcomes, 13 assessed emollients.

          We assessed most of the evidence in the review as low certainty and had some concerns about risk of bias. A rating of some concerns was most often due to lack of blinding of outcome assessors or significant missing data, which could have impacted outcome measurement but was judged unlikely to have done so. We assessed the evidence for the primary food allergy outcome as high risk of bias due to the inclusion of only one trial, where findings varied based on different assumptions about missing data.

          Skin care interventions during infancy probably do not change the risk of eczema by one to three years of age (risk ratio (RR) 1.03, 95% confidence interval (CI) 0.81 to 1.31; risk difference 5 more cases per 1000 infants, 95% CI 28 less to 47 more; moderate‐certainty evidence; 3075 participants, 7 trials) or time to onset of eczema (hazard ratio 0.86, 95% CI 0.65 to 1.14; moderate‐certainty evidence; 3349 participants, 9 trials). Skin care interventions during infancy may increase the risk of IgE‐mediated food allergy by one to three years of age (RR 2.53, 95% CI 0.99 to 6.49; low‐certainty evidence; 976 participants, 1 trial) but may not change risk of allergic sensitisation to a food allergen by age one to three years (RR 1.05, 95% CI 0.64 to 1.71; low‐certainty evidence; 1794 participants, 3 trials). Skin care interventions during infancy may slightly increase risk of parent report of immediate reaction to a common food allergen at two years (RR 1.27, 95% CI 1.00 to 1.61; low‐certainty evidence; 1171 participants, 1 trial); however, this was only seen for cow’s milk, and may be unreliable due to over‐reporting of milk allergy in infants. Skin care interventions during infancy probably increase risk of skin infection over the intervention period (RR 1.33, 95% CI 1.01 to 1.75; risk difference 17 more cases per 1000 infants, 95% CI one more to 38 more; moderate‐certainty evidence; 2728 participants, 6 trials) and may increase the risk of infant slippage over the intervention period (RR 1.42, 95% CI 0.67 to 2.99; low‐certainty evidence; 2538 participants, 4 trials) and stinging/allergic reactions to moisturisers (RR 2.24, 95% 0.67 to 7.43; low‐certainty evidence; 343 participants, 4 trials), although CIs for slippages and stinging/allergic reactions were wide and include the possibility of no effect or reduced risk.

          Preplanned subgroup analyses showed that the effects of interventions were not influenced by age, duration of intervention, hereditary risk, filaggrin ( FLG) mutation, chromosome 11 intergenic variant rs2212434,   or classification of intervention type for risk of developing eczema. We could not evaluate these effects on risk of food allergy. Evidence was insufficient to show whether adherence to interventions influenced the relationship between skin care interventions and eczema or food allergy development.

          Authors' conclusions

          Based on low‐ to moderate‐certainty evidence, skin care interventions such as emollients during the first year of life in healthy infants are probably not effective for preventing eczema; may increase risk of food allergy; and probably increase risk of skin infection. Further study is needed to understand whether different approaches to infant skin care might prevent eczema or food allergy.

          Plain language summary

          Skin care interventions for preventing eczema and food allergy

          Does moisturising baby skin prevent eczema or food allergies?

          Key messages

          Skin care treatments in babies, such as using moisturisers on the skin during the first year of life, probably do not prevent babies from developing eczema; may increase the chance of food allergy; and probably increase the chance of skin infection. This review looked at the prevention of eczema and food allergy only. Skin care treatments are still important to treat eczema. 

          What are allergies?

          An immune response is how the body recognises and defends itself against substances that appear harmful. An allergy is a reaction of the body's immune system to a particular food or substance (an allergen) that is usually harmless. Different allergies affect different parts of the body, and their effects can be mild or serious.

          Food allergies and eczema

          Eczema is a common skin condition  that causes dry, itchy, cracked skin. Eczema is common in children, often developing before their first birthday, and may be long‐lasting.

          Allergies to food can cause itching in the mouth, a raised itchy red rash, swelling of the face, stomach symptoms, or difficulty breathing. They usually happen within two hours after a food is eaten.

          People with food allergies often have other allergic conditions, such as asthma, hay fever, and eczema.

          Why we did this Cochrane Review

          We wanted to learn how skin care affects the risk of a baby developing eczema or food allergies. Skin care treatments included:

          • putting moisturisers on a baby's skin;

          • bathing babies with water containing moisturisers or moisturising oils;

          • advising parents to use less soap, or to bathe their child less often;

          • using water softeners. 

          We also wanted to know if these skin care treatments cause any unwanted effects. 

          What did we do?

          We searched for studies of different types of skin care for healthy babies (aged up to one year) with no previous food allergy, eczema, or other skin condition.

          Search date: we incorporated evidence published up to July 2021.

          We were interested in studies that reported:

          • how many children developed eczema, or food allergy, by age one to three years;

          • how severe the eczema was (according to a researcher and to parents);

          • how long it took for eczema to develop;

          • parents' reports of immediate (under two hours) reactions to a food allergen;

          • how many children developed sensitivity to a particular food allergen;

          • any unwanted effects.

          We assessed the strengths and weaknesses of each study to determine how reliable the results might be, and then combined the results of the relevant studies and looked at overall effects.  

          What we found

          We found 33 studies, involving 25,827 babies, that assessed any type of skin intervention. The included studies took place in Europe, Australia, Japan, and the USA, most often at children's hospitals. Skin care was compared against no skin care or usual skin care for babies in that country. Treatment and follow‐up times ranged from 24 hours to three years. Many studies (13) tested the use of moisturisers; the other studies mainly tested the use of bathing and cleansing products and how often they were used.

          Of the 33 included studies, only 11 studies had comparable outcomes of eczema, food allergy, or adverse effects and were combined for analysis. All of these studies enrolled babies before they were one month old, and  eight of these studies included babies thought to be at high risk for developing eczema. 

          What are the main results of our review?

          Compared to no skin care or standard care, moisturisers:

          • probably do not change the chance of developing eczema by age one to three years (7 studies; 3075 babies), or the time needed for eczema to develop (9 studies; 3349 babies);

          • may increase the chance of developing a food allergy as judged by a researcher (1 study; 976 babies) by age one to three years;

          • may slightly increase the number of immediate reactions to a common food allergen at two years, as reported by parents (1 study; 1171 babies);

          • probably cause more skin infections (6 studies; 2728 babies);

          • may increase unwanted effects, such as a stinging feeling or an allergic reaction to moisturisers (4 studies; 343 babies);

          • may increase the chance of babies slipping (4 studies; 2538 babies);

          • may not affect the chance of developing sensitivity to food allergens (3 studies; 1797 babies) by age one to three years.

          Confidence in our results

          We are moderately confident in our results for developing eczema and the time needed to develop eczema. We are less confident about our results for food allergy or sensitivity, which are based on small numbers of studies with widely varying results. These results are likely to change when more evidence becomes available. Our confidence in the review findings for skin infections is moderate, but low for stinging or allergic reactions and slipping. 

          Related collections

          Most cited references292

          • Record: found
          • Abstract: not found
          • Article: not found

          Measuring inconsistency in meta-analyses.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Bias in meta-analysis detected by a simple, graphical test

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis.

              Atopic disease, including atopic dermatitis (eczema), allergy and asthma, has increased in frequency in recent decades and now affects approximately 20% of the population in the developed world. Twin and family studies have shown that predisposition to atopic disease is highly heritable. Although most genetic studies have focused on immunological mechanisms, a primary epithelial barrier defect has been anticipated. Filaggrin is a key protein that facilitates terminal differentiation of the epidermis and formation of the skin barrier. Here we show that two independent loss-of-function genetic variants (R510X and 2282del4) in the gene encoding filaggrin (FLG) are very strong predisposing factors for atopic dermatitis. These variants are carried by approximately 9% of people of European origin. These variants also show highly significant association with asthma occurring in the context of atopic dermatitis. This work establishes a key role for impaired skin barrier function in the development of atopic disease.
                Bookmark

                Author and article information

                Journal
                Cochrane Database Syst Rev
                Cochrane Database Syst Rev
                14651858
                10.1002/14651858
                The Cochrane Database of Systematic Reviews
                John Wiley & Sons, Ltd (Chichester, UK )
                1469-493X
                14 November 2022
                2022
                14 November 2022
                : 2022
                : 11
                : CD013534
                Affiliations
                deptNational Heart & Lung Institute, Section of Inflammation and Repair Imperial College London LondonUK
                deptImperial Clinical Trials Unit Imperial College London LondonUK
                deptCentre for Genomic and Experimental Medicine University of Edinburgh EdinburghUK
                deptDivision of Paediatric and Adolescent Medicine Oslo University Hospital OsloNorway
                deptFaculty of Medicine, Institute of Clinical Medicine University of Oslo OsloNorway
                deptDepartment of Dermatology Oslo University Hospital OsloNorway
                deptAllergy and Lung Health Unit, Melbourne School of Population and Global Health University of Melbourne MelbourneAustralia
                deptDepartment of Pediatrics University of Wisconsin School of Medicine and Public Health MadisonWisconsinUSA
                deptCenter for Preventive Medical Sciences Chiba University ChibaJapan
                deptDepartment of Midwifery and Women's Health Graduate School of Medicine, The University of Tokyo TokyoJapan
                deptAllergy Center National Center for Child Health and Development TokyoJapan
                deptDepartment of Pediatrics Keio University School of Medicine TokyoJapan
                deptCentre of Evidence Based Dermatology University of Nottingham NottinghamUK
                deptSheffield Dermatology Research, Department of Infection, Immunity & Cardiovascular Disease The University of Sheffield SheffieldUK
                deptDivision of Nursing, Midwifery and Social Work, School of Health Sciences The University of Manchester ManchesterUK
                deptCenter for Evidence-Based Healthcare Faculty of Medicine Carl Gustav Carus, Technischen Universität (TU) Dresden DresdenGermany
                deptDepartment of Dermatology and Allergy University Hospital Scheswig-Holstein KielGermany
                deptDepartment of Dermatology Oregon Health & Science University PortlandOregonUSA
                deptNottingham Clinical Trials Unit University of Nottingham NottinghamUK
                deptNHMRC Clinical Trials Centre University of Sydney CamperdownAustralia
                deptCochrane Skin, Centre of Evidence Based Dermatology University of Nottingham NottinghamUK
                Article
                CD013534.pub3 CD013534
                10.1002/14651858.CD013534.pub3
                9661877
                36373988
                66d9d6fe-4504-4c97-b3db-398ca373de57
                Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

                This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                Categories
                C. DERMATITIS AND ECZEMA

                Comments

                Comment on this article